Hims & Hers Health Inc
NYSE:HIMS
Hims & Hers Health Inc
Once upon a time in the bustling landscape of telehealth services, Hims & Hers Health Inc. emerged as a pioneering force, reshaping the narrative around personal wellness and healthcare accessibility. Founded with a direct-to-consumer approach, the company cleverly positioned itself at the intersection of convenience and necessity. Operating primarily through an online platform, Hims & Hers offers a range of health-related products and services targeting conditions often stigmatized or considered sensitive, such as hair loss, erectile dysfunction, skincare, mental health, and more. The company’s business model hinges on its ability to bypass traditional healthcare barriers, providing easy access to licensed healthcare professionals and personalized treatment plans through a seamless internet-based interface.
Their revenue model is multifaceted, but at its core are product sales and subscription services. Customers begin their journey by completing a brief online consultation, which, in many states, can involve a healthcare professional reviewing their information without an in-person visit. Once approved, the company's network of telehealth providers prescribes medications, which are conveniently delivered to customers’ doorsteps. Whether purchasing single products or opting for monthly subscriptions, users are drawn to the discretion and accessibility of the service. Hims & Hers markets its offerings directly through savvy digital campaigns, leveraging the power of modern e-commerce to reach younger demographics who appreciate privacy and efficiency in managing their health. Thus, the company stands as a compelling example of how technology can democratize healthcare, wrapped seamlessly within the bounds of consumer-friendly digital infrastructure.
Once upon a time in the bustling landscape of telehealth services, Hims & Hers Health Inc. emerged as a pioneering force, reshaping the narrative around personal wellness and healthcare accessibility. Founded with a direct-to-consumer approach, the company cleverly positioned itself at the intersection of convenience and necessity. Operating primarily through an online platform, Hims & Hers offers a range of health-related products and services targeting conditions often stigmatized or considered sensitive, such as hair loss, erectile dysfunction, skincare, mental health, and more. The company’s business model hinges on its ability to bypass traditional healthcare barriers, providing easy access to licensed healthcare professionals and personalized treatment plans through a seamless internet-based interface.
Their revenue model is multifaceted, but at its core are product sales and subscription services. Customers begin their journey by completing a brief online consultation, which, in many states, can involve a healthcare professional reviewing their information without an in-person visit. Once approved, the company's network of telehealth providers prescribes medications, which are conveniently delivered to customers’ doorsteps. Whether purchasing single products or opting for monthly subscriptions, users are drawn to the discretion and accessibility of the service. Hims & Hers markets its offerings directly through savvy digital campaigns, leveraging the power of modern e-commerce to reach younger demographics who appreciate privacy and efficiency in managing their health. Thus, the company stands as a compelling example of how technology can democratize healthcare, wrapped seamlessly within the bounds of consumer-friendly digital infrastructure.
Strong Revenue Growth: Hims & Hers reported Q4 revenue of $618 million, up 28% year-over-year, and full year 2025 revenue of $2.35 billion, up 59% year-over-year.
Profitability: The company achieved full-year net income of $128 million and adjusted EBITDA of $318 million, nearly 80% higher than 2024.
Subscriber Base: Subscribers grew to over 2.5 million, with approximately 1.6 million using personalized treatments.
Expansion & M&A: International revenue surged nearly 400% to $134 million, driven by acquisitions like ZAVA and Livewell, and the upcoming Eucalyptus deal aims to deepen global reach.
2026 Guidance: Projected 2026 revenue of $2.7–$2.9 billion (up 15–24% YoY) and adjusted EBITDA of $300–$375 million, with margin midpoint guidance at 12%.
GLP-1s & Diversification: While GLP-1s have accelerated growth, the majority of revenue and profits still come from non-GLP-1 offerings, underscoring business diversification.
Strategic Investments: Significant investments continue in technology, AI, personalized care, and infrastructure, with over $300 million spent on facilities and R&D over the last 3 years.
